CSIMarket Company Name, Ticker, Customers, else..
 
Sonnet Biotherapeutics Holdings Inc   (NASDAQ: SONN)
 

Sonnet Biotherapeutics Holdings Inc's Suppliers Performance

SONN's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
SONN Costs vs Sales of Suppliers Growth

• More on SONN Suppliers






Sonnet Biotherapeutics Holdings Inc's Comment on Supply Chain


The company utilizes a current contract development and manufacturing organization (CDMO) that has expanded production capacity and is constructing a cGMP manufacturing facility in the United States, expected to be operational by the third quarter of 2024. The company has not engaged alternative suppliers, as the existing CDMO continues to manufacture its pipeline products successfully. Relationships with CDMOs are overseen by experienced internal personnel. The company has a collaboration agreement with Janssen Biotech, Inc. to evaluate certain compounds in combination with Janssen's proprietary cell therapy assets. Additionally, the company has an exclusive license agreement with Alkem Laboratories Limited for the development and commercialization of pharmaceutical products containing its IL-6 (SON-080) asset in India. The company will manufacture compounds and products for Alkem under a follow-on supply agreement to be negotiated.

Sonnet Biotherapeutics Holdings Inc's Comment on Supply Chain


The company utilizes a current contract development and manufacturing organization (CDMO) that has expanded production capacity and is constructing a cGMP manufacturing facility in the United States, expected to be operational by the third quarter of 2024. The company has not engaged alternative suppliers, as the existing CDMO continues to manufacture its pipeline products successfully. Relationships with CDMOs are overseen by experienced internal personnel. The company has a collaboration agreement with Janssen Biotech, Inc. to evaluate certain compounds in combination with Janssen's proprietary cell therapy assets. Additionally, the company has an exclusive license agreement with Alkem Laboratories Limited for the development and commercialization of pharmaceutical products containing its IL-6 (SON-080) asset in India. The company will manufacture compounds and products for Alkem under a follow-on supply agreement to be negotiated.







SONN's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Sonnet Biotherapeutics Holdings Inc 5.20 0.35 -16.01 9
SUBTOTAL 0.00 0.00 0.00 -


Sources: Sonnet Biotherapeutics Holdings Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Sonnet Biotherapeutics Holdings Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.